Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 586 across all filing types
Latest filing 2020-01-08 Director's Dealing
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2020-01-08 English
FORM 3 SUBMISSION
Director's Dealing
2020-01-08 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 7, 2020, by Sutro Biopharma, Inc. The content focuses on the appointment of a new director, James Panek, to the Board of Directors, including details about his compensation and indemnification agreement. There is no financial data or report content, but rather an announcement of a change in the company's board. This matches the description for Board/Management Information (MANG). The document length is 4543 characters, which is consistent with a typical 8-K announcement of management changes rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2020-01-08 English
FORM 4 SUBMISSION
Director's Dealing
2019-12-27 English
FORM 4 SUBMISSION
Director's Dealing
2019-11-27 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is Item 2.02, which states the company issued a press release announcing financial results for the period ended June 30, 2019, and the press release is attached as Exhibit 99.1. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes a press release. The length is 3623 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document announcing the release of financial results but not containing the full financial data should be classified as an Earnings Release (ER) if it contains key highlights only. The document references financial results and includes a press release with results, which fits the Earnings Release category. Therefore, the classification is ER with high confidence.
2019-11-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.